Asymmetrical dimethylarginine is increased in plasma and decreased in cerebrospinal fluid of patients with Alzheimer's disease

Dementia and Geriatric Cognitive Disorders

Volumn 26, Issue 1, 2008, Pages 58-64

  Arlt, Sönke ^a,b   Schulze, Friedrich ^a   Eichenlaub, Martin ^a   Maas, Renke ^a   Lehmbeck, Jan T ^a   Schwedhelm, Edzard ^a   Jahn, Holger ^a   Böger, Rainer H ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Alzheimer's disease; Asymmetrical dimethylarginine; Cerebrospinal fluid

Indexed keywords

N(G),N(G) DIMETHYLARGININE;

AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD LEVEL; CEREBROSPINAL FLUID LEVEL; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PRIORITY JOURNAL;

AGED; ALZHEIMER DISEASE; ARGININE; BIOLOGICAL MARKERS; BODY MASS INDEX; CASE-CONTROL STUDIES; COGNITION DISORDERS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; NITRIC OXIDE; OXIDATIVE STRESS; PEROXYNITROUS ACID; RISK FACTORS;

EID: 47949116906     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000144026     Document Type: Article

References (36)

1. Hawkins RD: No honey, I don't remember. Neuron 1996;16:465-467.
2. Forstermann U, Munzel T: Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 2006;113:1708-1714.
3. Colton CA, Vitek MP, Wink DA, Xu Q, Cantillana V, Previti ML, Van Nostrand WE, Weinberg JB, Dawson H: NO synthase 2 (NOS2) deletion promotes multiple pathologies in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2006;103:12867-12872.
4. Vallance P, Leone A, Calver A, Collier J, Moncada S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-575.
5. Nakajima T, Matsuoka Y, Kakimoto Y: Isolation and identification of N-G-monomethyl, N-G, N-G-dimethyl- and N-G,N′ G-dimethylarginine from the hydrolysate of proteins of bovine brain. Biochim Biophys Acta 1971;230:212-222.
6. Kielstein JT, Impraim B, Simmel S, Bode-Boger SM, Tsikas D, Frolich JC, Hoeper MM, Haller H, Fliser D: Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 2004;109:172-177.
7. Perticone F, Sciacqua A, Maio R, Perticone M, Maas R, Boger RH, Tripepi G, Sesti G, Zoccali C: Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol 2005;46:518-523.
8. Schulze F, Lenzen H, Hanefeld C, Bartling A, Osterziel KJ, Goudeva L, Schmidt-Lucke C, Kusus M, Maas R, Schwedhelm E, Strodter D, Simon BC, Mugge A, Daniel WG, Tillmanns H, Maisch B, Streichert T, Boger RH: Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter coronary artery risk determination investigating the influence of ADMA concentration (CARDIAC) study. Am Heart J 2006;152:493.e1-493.e8.
9. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP: Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998;98:1842-1847.
10. Abbasi F, Asagmi T, Cooke JP, Lamendola C, McLaughlin T, Reaven GM, Stuehlinger M, Tsao PS: Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001;88:1201-1203.
11. Teerlink T: Measurement of asymmetric dimethylarginine in plasma: methodological considerations and clinical relevance. Clin Chem Lab Med 2005;43:1130-1138.
12. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frolich J, Boger R: Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001;358:2113-2117.
13. Schnabel R, Blankenberg S, Lubos E, Lackner KJ, Rupprecht HJ, Espinola-Klein C, Jachmann N, Post F, Peetz D, Bickel C, Cambien F, Tiret L, Munzel T: Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the atherogene study. Circ Res 2005;97:e53-e59.
14. Maas R, Schulze F, Baumert J, Lowel H, Hamraz K, Schwedhelm E, Koenig W, Boger RH: Asymmetric dimethylarginine, smoking, and risk of coronary heart disease in apparently healthy men: prospective analysis from the population-based monitoring of trends and determinants in cardiovascular disease/Kooperative Gesundheitsforschung in der Region Augsburg study and experimental data. Clin Chem 2007;53:693-701.
15. Kielstein JT, Donnerstag F, Gasper S, Menne J, Kielstein A, Martens-Lobenhoffer J, Scalera F, Cooke JP, Fliser D, Bode-Boger SM: ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke 2006;37:2024-2029.
16. Wanby P, Teerlink T, Brudin L, Brattstrom L, Nilsson I, Palmqvist P, Carlsson M: Asymmetric dimethylarginine (ADMA) as a risk marker for stroke and TIA in a Swedish population. Atherosclerosis 2006;185:271-277.
17. Selley ML: Increased concentrations of homocysteine and asymmetric dimethylarginine and decreased concentrations of nitric oxide in the plasma of patients with Alzheimer's disease. Neurobiol Aging 2003;24:903-907.
18. Abe T, Tohgi H, Murata T, Isobe C, Sato C: Reduction in asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in the cerebrospinal fluid during aging and in patients with Alzheimer's disease. Neurosci Lett 2001;312:177-179.
19. Mulder C, Wahlund LO, Blomberg M, de Jong S, van Kamp GJ, Scheltens P, Teerlink T: Alzheimer's disease is not associated with altered concentrations of the nitric oxide synthase inhibitor asymmetric dimethylarginine in cerebrospinal fluid. J Neural Transm 2002;109:1203-1208.
20. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
21. Folstein MF, Folstein SE, McHugh PR: 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
22. Schulze F, Wesemann R, Schwedhelm E, Sydow K, Albsmeier J, Cooke JP, Boger RH: Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin Chem Lab Med 2004;42:1377-1383.
23. Schulze F, Maas R, Freese R, Schwedhelm E, Silberhorn E, Boger RH: Determination of a reference value for N(G), N(G)-dimethyl-L-arginine in 500 subjects. Eur J Clin Invest 2005;35:622-626.
24. Schwedhelm E, Tan-Andresen J, Maas R, Riederer U, Schulze F, Boger RH: Liquid chromatography-tandem mass spectrometry method for the analysis of asymmetric dimethylarginine in human plasma. Clin Chem 2005;51:1268-1271.
25. Schwedhelm E, Maas R, Tan-Andresen J, Schulze F, Riederer U, Boger RH: High-throughput liquid chromatographic-tandem mass spectrometric determination of arginine and dimethylated arginine derivatives in human and mouse plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2007;851:211-219.
26. Gorelick PB: Risk factors for vascular dementia and Alzheimer disease. Stroke 2004;35:2620-2622.
27. Borroni B, Akkawi N, Martini G, Colciaghi F, Prometti P, Rozzini L, Di Luca M, Lenzi GL, Romanelli G, Caimi L, Padovani A: Microvascular damage and platelet abnormalities in early Alzheimer's disease. J Neurol Sci 2002;203-204:189-193.
28. Boger RH: Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med 2006;38:126-136.
29. Park SH, Lee HW, Kim S, Paik WK: A peptide inhibitor for S-adenosyl-L-methionine-dependent transmethylation reactions. Purification and characterization. Int J Biochem 1993;25:1157-1164.
30. Leiper JM, Santa Maria J, Chubb A, MacAllister RJ, Charles IG, Whitley GS, Vallance P: Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J 1999;343:209-214.
31. Bottiglieri T, Godfrey P, Flynn T, Carney MW, Toone BK, Reynolds EH: Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. J Neurol Neurosurg Psychiatry 1990;53:1096-1098.
32. Morrison LD, Smith DD, Kish SJ: Brain S-adenosylmethionine levels are severely decreased in Alzheimer's disease. J Neurochem 1996;67:1328-1331.
33. Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G: Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 1997;17:2653-2657.
34. McCaddon A, Davies G, Hudson P, Tandy S, Cattell H: Total serum homocysteine in senile dementia of Alzheimer type. Int J Geriatr Psychiatry 1998;13:235-239.
35. Selley ML, Close DR, Stern SE: The effect of increased concentrations of homocysteine on the concentration of (E)-4-hydroxy-2-nonenal in the plasma and cerebrospinal fluid of patients with Alzheimer's disease. Neurobiol Aging 2002;23:383-388.
36. de la Torre JC: Alzheimer disease as a vascular disorder: nosological evidence. Stroke 2002;33:1152-1162.